The urokinase receptor (CD87) represents a central mediator of growth factor-induced endothelial cell migration

Thrombosis and Haemostasis

Volumn 108, Issue 2, 2012, Pages 357-366

  Poettler, Marina ^a   Unseld, Matthias ^a   Mihaly Bison, Judit ^a   Uhrin, Pavel ^a   Koban, Florián ^a   Binder, Bernd R ^a   Zielinski, Christoph C ^a   Prager, Gerald W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angiogenesis; Endothelial cells; Growth factors; UPA plasminogen system

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL) CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL) IMIDAZOLE; D DIMER; FIBROBLAST GROWTH FACTOR 2; LOW DENSITY LIPOPROTEIN RECEPTOR; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; SCATTER FACTOR; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN 165; VASCULOTROPIN E; WORTMANNIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CYTOFLUOROMETRY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

CELL LINE; CELL MOVEMENT; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; FLOW CYTOMETRY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICROCIRCULATION; MICROSCOPY, VIDEO; NEOVASCULARIZATION, PHYSIOLOGIC; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84870365365     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-12-0868     Document Type: Article

References (42)

1. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-395.
2. Schmidt-Erfurth U E, et al. Efficacy and safety of monthly versus quarterly ranib-izumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011; 118: 831-839.
3. Gerger A, et al. Molecular predictors of response to antiangiogenesis therapies. Cancer J 2011; 17: 134-141.
4. Fischer C, et al. FLT1 and its ligands VEGFB and P1GF: drug targets for anti-angio-genic therapy? Nat Rev Cancer 2008; 8: 942-956.
5. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
6. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol2010; 11:23-36.
7. Prager GW, et al. Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood 2004; 103: 955-962.
8. Prager GW, et al. Vascular Endothelial Growth Factor Receptor-2-Induced Initial Endothelial Cell Migration Depends on the Presence of the Urokinase Receptor. Circ Res 2004; 94: 1562-1570.
9. Nykjaer A, et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 1997; 16:2610-2620.
10. Tarui T, et al. Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem 2001; 276: 3983-3990.
11. Wei Y, et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-1555.
12. Felsenfeld DP, et al. Ligand binding regulates the directed movement of betal integrins on fibroblasts. Nature 1996; 383: 438-440.
13. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell 1996; 84: 359-369.
14. Lawson MA, Maxfield FR. Ca(2+)- and calcineurin-dependent recycling of an integrin to the front of migrating neutrophils. Nature 1995; 377: 75-79.
15. Schwarz HP, et al. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice. Blood 2000; 95: 1703-1708.
16. Mechtcheriakova D, et al. Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001; 15:230-242.
17. Huber J, et al. The Isoprostane 8-iso-PGE(2) Stimulates Endothelial Cells to Bind Monocytes via Cyclic AMP- and p38 MAP Kinase-Dependent Signaling Pathways. Anti oxid Redox Signal 2003; 5: 163-169.
18. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-936.
19. Mochizuki Y, et al. Negative regulation of urokinase-type plasminogen activator production through FGF-2-mediated activation of phosphoinositide 3-kinase. Oncogene 2002; 21: 7027-7033.
20. Zubilewicz A, et al. Two distinct signalling pathways are involved in FGF2-stimu-lated proliferation of choriocapillary endothelial cells: a comparative study with VEGF. Oncogene 2001; 20:1403-1413.
21. Karsan A, et al. Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. Am J Pathol 1997; 151: 1775-1784.
22. Matsumoto T, et al. p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis. J Cell Biol 2002; 156:149-160.
23. 1, ZD1839). Cancer Sci 2004; 95: 614-618.
24. Sengupta S, et al. Targeting of mitogen-activated protein kinases and phosphati-dylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis. Circulation 2003; 107: 2955-2961.
25. Goldman E. The growth of malignant disease in man and the lower animals with special reference to the vascular system. Lancet 1907; 2: 1236-1240.
26. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
27. Prager GW, Poettler M. Angiogenesis in cancer. Basic mechanisms and therapeutic advances. Hamostaseologie 2012; 32: 105-114.
28. Cassidy J, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for meta-static colorectal cancer. J Clin Oncol 2008; 26:2006-2012.
29. Saltz LB, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
30. Loges S, et al. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15:167-170.
31. Malla RR, et al. Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma. Cancer Gene Ther 2011; 18:419-434.
32. Alexander RA, et al. VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution. Cardiovasc Res 2012; 94: 125-135.
33. Czekay RP, et al. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003; 160: 781-791.
34. Prager GW, et al. Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein. Blood 2009; 113:1383-1390.
35. Brunner PM, et al. Density enhanced phosphatase-1 down-regulates urokinase receptor surface expression in confluent endothelial cells. Blood 2011; 117: 4154-4161.
36. Schmitt M, et al. Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2010; 10: 1051-1067.
37. Buchler P, et al. Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia 2009; 11: 196-206.
38. Kietzmann T, et al. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 1999; 94:4177-4185.
39. Paez-Ribes M, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
40. Ebos JM, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-239.
41. Nozaki S, et al. Targeting urokinase-type plasminogen activator and its receptor for cancer therapy. Anticancer Drugs 2006; 17:1109-1117.
42. Kenny HA, et al. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res 2011; 17: 459-471.